Huma builds regulated Software as a Medical Device (SaMD) solutions
Building a SaMD is complex. Launching it across several continents is even more challenging, but the hardest part is scaling and sustaining it across thousands of hospitals, clinics and patients. When you see our technology, infrastructure and innovation in operation, you will understand why some of the world's biggest life science companies have chosen to use Huma.Talk to us
Winner of the 2021 Prix Galien award for digital health (“pharma’s Nobel prize”)
Active users across our platforms
Adherence and retention rates across our care and research deployments
Devices have been shipped in support of our projects
Hospitals and clinics use our technologies to make sustainable impacts for patients
Huma’s health platform is having a global impact across a network of 27m patients
We advance connected care, helping you build and scale complex SaMD digital companions that are intuitive to use and eagerly adopted.
Our experienced team of Engineers, Designers, Clinicians and Project Managers can rapidly launch and sustain bespoke products with our device, disease and cloud agnostic platform. We already support more than 1.8 million active users across 3,000 hospitals and clinics with consistently high engagement scores.
Modular or bespoke
Highest quality management and regulatory standards
Leading data security and privacy standards
Strong regulatory team
Track record to deploy at scale
Adherence and user engagement
Data science capabilities
Assist go-to-market and commercialisation
Speed your way to
Ready-to-deploy, proven modules
Secure, scalable, and fully compliant: our platform accelerates time to market for regulated digital health products — including companion apps, patient support and engagement programs, device/software combinations and algorithms.
Our ready-to-deploy modules include:
Timeline and notifications
Carers and proxies
Mental health support
Improving patient outcomes
Prevention and early diagnosis
Patient support and engagement
Dose management and titration
Optimise disease management
Learn from every case
Generate real world data
Registered and able to immediately place products in 33 countries.
Capable of supporting all language requirements.
Self-service modular platform to enable rapid configuration.
"The Most Important Healthcare Design of 2021" by Fast Company
Industry-leading and flexible IoMT integration
Built to the highest data, privacy and security standards
Cloud-agnostic platform that can run on any system
Can be deployed globally across multiple therapeutic areas
Connect with us and our partners
We have successfully deployed some of the largest SaMD solutions across multiple patient populations, including heart failure, cardio metabolic disease, pulmonary hypertension and more.
EU MDD & MDR
21CFR820 US FDA Class I exempt
Approved Pharma Supplier
Global Regulatory Footprint
Talk to us
The full report is available on request. Patient feedback based on sample size of 30 responses.
2. Data from 2021 pilot study. Full evaluation of the service is in preparation.
3. Source: Dolezalova, N., Reed, A.B., Despotovic, A., Obika, B.D., Morelli, D., Aral, M. and Plans, D., 2021. Development of an accessible 10-year Digital CArdioVAscular (DiCAVA) risk assessment: a UK Biobank study. arXiv preprint arXiv:2104.10079.
4. Data from 2021 pilot study, results pending publication.